European Neurology
Original Paper
Adrenoleukodystrophy Associated with Vitiligo and Ulcerative ColitisSawaya R.A.a · Mourad F.H.a · Najjar S.b · Mikati M.b · Raymond G.V.cDepartments of aInternal Medicine and bPediatrics, American University Medical Center, Beirut, Lebanon; and cKennedy Kriger Institute, Baltimore, Md., USA
|
|
Eur Neurol 1999;42:169–172
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Published online: October 08, 1999
Issue release date: October 1999
Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 0
ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)
For additional information: https://www.karger.com/ENE
Abstract
Adrenoleukodystrophy (ALD) is an X-linked inherited disorder of lipid metabolism usually presenting in childhood or early adolescence. It is a progressive disease with symptoms of adrenal insufficiency and central nervous system demyelination. The pathology results from the accumulation of very long-chain fatty acids and an inflammatory reaction in the brain white matter. We report a case of ALD associated with adrenal insufficiency and two autoimmune diseases: vitiligo and ulcerative colitis.
Related Articles:
References
- Sadeghi-Nejad A, Senior B: Adrenoleukodystrophy presenting as Addison’s disease in childhood. N Engl J Med 1990;322:13–16.
-
Rizzo W: X-linked adrenoleukodystrophy: A cause of primary adrenal insufficiency in males. Endocrinologist 1992;2:177–183.
-
Larveti S, Casucci G, Santensanino F, Angeletti G, Aubourg P, Brunetti P: X-linked adrenoleukodystrophy is a frequent cause of idiopathic Adisson’s disease in young adult male patients. J Clin Endocrinol 1996;81:470–474.
-
Whelan G: Epidemiology of inflammatory bowel disease. Med Clin North Am 1990;74:1–49.
External Resources
- Willems P, Vits L, Wanders R, Coucke P, Van der Auwera B, Van Elsen A, et al: Linkage of DNA markers at Xq28 to adrenoleukodystrophy and adrenomyeloneuropathy present within the same family. Arch Neurol 1990;47:665–669.
-
Maris T, Androulidakis EJ, Tzagournissakis M, Papavassiliou S, Moser H, Plaitakis A: X-linked adrenoleukodystrophy presenting as neurologically pure familial spastic paraparesis. Neurology 1994;45:1101–1104.
External Resources
- O’Neil B, Forbes G, Gomez M, Zimmerman D, Barrier H, Moser H: A comparison of magnetic resonance imaging (MRI) and computed tomography (CT) in adrenoleukodystrophy (ALD). Neurology 1985;35:83–89.
-
Federico A, Dotti MT, Annunziata P, Bonuccelli U, Fenzi G, Ciacci G, Malandrini A, Meucci G, Guazzi GC: Adrenomyeloneurodystrophy with late cerebral involvement and evidence of a multiple autoimmune disorder. J Inherited Metab Dis 1998;11(suppl 2):169–172.
-
Snook JA, Silva HJ, Jewell DP: The association of autoimmune disorders with inflammatory bowel disease. Q J Med 1989;269:835–840.
-
Govindarajan R, Galpin OP: Coexistence of Addison’s disease, ulcerative colitis, hypothyroidism and pernicious anemia. J Clin Gastroenterol 1992;15:82–83.
-
Moser HW, Moser AB: Measurement of saturated very long chain fatty acids in plasma; in Hommes FA (ed): Techniques in Diagnostic Biochemical Genetics: A Laboratory Manual. New York, Wiley-Liss, 1991, pp 177–191.
- Rizzo WB, Phillips MW, Dammann AL: Adrenoleukodystrophy: Dietary oleic acid lowers hexacosanoate levels. Ann Neurol 1987;21:232–239.
- Aubourg P, Adamsbaum C, Lavallard-Rousseau M, Rocchiccioli F, Cartier N, Jambaque I, et al: A two year trial of oleic and erucic acids (‘Lorenzo’s Oil’) as treatment for adrenomyeloneuropathy. N Engl J Med 1993;329:745–751.
- Saurat JH, Itin P: Peroxisome disorders and cutaneous manifestations. Dermatology 1994;188:1–2.
-
Ryan TJ: Skin disorders; in Weatherall DJ, Ledingham JGG (eds): Oxford Textbook of Medicine, ed 3. New York, Oxford University Press, 1996, vol 3, pp 3755–3759.
- Schreiber S, Raedler A, Stenson WF, MacDesmott RP: The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin North Am 1992;21:451–502.
- Kinoshita M, Saito E, Kawamura T, Yamada N, Nakazato H: Adult adrenoleukodystrophy with hypercortisolemia. Jpn J Med 1986;25:63–68.
- Shanakan F: Pathogenesis of ulcerative colitis. Lancet 1993;342:407–411.
- Kumar AJ, Kohler W, Kruse B, Naidu S, Bergin A, Edwin D, Moser HW: MR findings in adult-onset adrenoleukodystrophy. Am J Neuroradiol 1995;16:1227–1237.
- Chaudhry V, Moser HW, Cornblath DR: Nerve conduction studies in adrenomyeloneuropathy. Neurosurg Psychiatry 1996;61:181–185.
-
Cappa M, Bertini E, del Balzo P, Cambiaso P, Di Biase A, Salvati S: High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 1994;57(suppl):69–70.
- Miike T, Taku K, Tamura T: Clinical improvement of adrenoleukodystrophy following intravenous gammaglobulin therapy. Brain Dev 1989;11:134–137.
Article / Publication Details
First-Page Preview
Published online: October 08, 1999
Issue release date: October 1999
Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 0
ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)
For additional information: https://www.karger.com/ENE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
